Covid 19 Research using Clinical Trials (Home Page)
HP:0001096: KeratoconjunctivitisHPO
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (1)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3032 | topical steroids and cyclosporin-A Wiki | 1.00 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 Combined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis; a Pilot Study
To explore the feasibility of combined topical corticosteroid and topical cyclosporine-A in COVID-19 patients with acute keratoconjunctivitis.
NCT04451239 Keratonjunctivitis Drug: topical steroids and cyclosporin-A MeSH:Keratoconjunctivitis
HPO:Keratoconjunctivitis
Primary Outcomes
Description: eye itching, foreign body sensation, tearing, redness in the eye and eyelid swelling
Measure: Symptom improvement Time: 10-15 days
Description: conjunctival injection, discharge, presence of superficial punctate keratitis (SPK), pseudomembranes on tarsal conjunctiva
Measure: Signs improvement Time: 10-15 days
HPO Nodes
HP:0001096: Keratoconjunctivitis
Genes 45
GSN IL23R GJB2 IL12A HLA-B HLCS ERCC3 TARS1 ERAP1 MPLKIP FOXE3 UROS LBR B2M HLA-DRB1 CCR1 MPLKIP IARS2 BTD AEBP1 KLRC4 RNF125 BTNL2 ZMPSTE24 MEFV ERCC2 C4A IL12A-AS1 MAB21L1 UBAC2 ERCC2 TLR4 LMNA ERCC2 NLRP1 IL10 SCN9A NOD2 GATA1 FAS GTF2E2 GTF2H5 RNF113A AIRE STAT4 Protein Mutations 0
SNP 0
Primary Outcomes
Description: eye itching, foreign body sensation, tearing, redness in the eye and eyelid swelling
Measure: Symptom improvement Time: 10-15 daysDescription: conjunctival injection, discharge, presence of superficial punctate keratitis (SPK), pseudomembranes on tarsal conjunctiva
Measure: Signs improvement Time: 10-15 days